Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib-Reference-Cited by-同舟云学术

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

Published:2005 Issue:9 Volume:103 Page:1850-1855
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Marin David,Kaeda Jaspal S.,Andreasson Catharina,Saunders Sue M.,Bua Marco,Olavarria Eduardo,Goldman John M.,Apperley Jane F.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference20 articles.

1. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

2. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

3. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

4. Inhibition of Translation in Eukaryotic Systems by Harringtonine

5. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on ‘in vitro’ growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications;European Journal of Medical Research;2024-05-04

2. Transcription and Translation Inhibitors in Cancer Treatment;Frontiers in Chemistry;2020-04-21

3. Phytotherapeutics in cancer invasion and metastasis;Phytotherapy Research;2018-04-19

4. A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected;Oncology and Therapy;2018-03-15

5. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products;Molecular Cancer;2018-02-19